+1 (502) 904-2126   One Westbrook Corporate Center, Suite 300, Westchester, IL 60154, USA   Site Map
ISSN: 2574 -1241

Impact Factor : 0.548

  Submit Manuscript

Mini ReviewOpen Access

The Clinical Efficacy of Dabrafenib Plus Trametinib Combination Treatment in Stage III/Ⅳ BRAF-Mutated Melanoma

Volume 12 - Issue 1

Zhao Hongbing1, Zhang Xifeng2, Feng Ting Ting1 and Li Xiao Rui*1

  • Author Information Open or Close
    • 1Department of Oncology, China
    • 2Shang Qiu Medical School, China
    • *Corresponding author: Li Xiao Rui, Department of Oncology, Xinxiang, Henan, China

Received: December 04, 2018;   Published: December 13, 2018

DOI: 10.26717/BJSTR.2018.12.002205

Full Text PDF

To view the Full Article   Peer-reviewed Article PDF


The morbidity of cutaneous melanoma has continued to increase in recent years. Patients with stage III disease are at higher risk for recurrence after locoregional resection and many will ultimately die from metastatic melanoma. BRAF inhibitors vemurafenib and dabrafenib have significantly improved progression-free survival (PFS) and overall survival (OS) as single agents compared with cytotoxic chemotherapy. Acquired resistance to BRAF inhibitors inevitably develops, resulting in a median progression-free survival of 6 to 8 months. Several clinical trials with combination treatment of dabrafenib(150 mg twice daily) plus trametinib(2 mg once daily) in stage III/Ⅳ BRAF-mutated melanoma have been reported. These clinical trials identify combination treatment of dabrafenib plus trametinib as front-line therapy in stage III/Ⅳ BRAF-mutated melanoma.

Keywords :Dabrafenib; Trametinib; Braf; Mek; Mutant; Melanoma

Mini Review| Result| Conclusion| References|